These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 16039851

  • 21. Selective, orally active 5-HT1D receptor agonists as potential antimigraine agents.
    MacLeod AM, Street LJ, Reeve AJ, Jelley RA, Sternfeld F, Beer MS, Stanton JA, Watt AP, Rathbone D, Matassa VG.
    J Med Chem; 1997 Oct 24; 40(22):3501-3. PubMed ID: 9357515
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist.
    Glennon JC, Van Scharrenburg G, Ronken E, Hesselink MB, Reinders JH, Van Der Neut M, Long SK, Feenstra RW, McCreary AC.
    Synapse; 2006 Dec 15; 60(8):599-608. PubMed ID: 17001660
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Bicyclic heteroarylpiperazines as selective brain penetrant 5-HT6 receptor antagonists.
    Ahmed M, Briggs MA, Bromidge SM, Buck T, Campbell L, Deeks NJ, Garner A, Gordon L, Hamprecht DW, Holland V, Johnson CN, Medhurst AD, Mitchell DJ, Moss SF, Powles J, Seal JT, Stean TO, Stemp G, Thompson M, Trail B, Upton N, Winborn K, Witty DR.
    Bioorg Med Chem Lett; 2005 Nov 01; 15(21):4867-71. PubMed ID: 16143522
    [Abstract] [Full Text] [Related]

  • 26. 5-Piperazinyl-3-sulfonylindazoles as potent and selective 5-hydroxytryptamine-6 antagonists.
    Liu KG, Robichaud AJ, Bernotas RC, Yan Y, Lo JR, Zhang MY, Hughes ZA, Huselton C, Zhang GM, Zhang JY, Kowal DM, Smith DL, Schechter LE, Comery TA.
    J Med Chem; 2010 Nov 11; 53(21):7639-46. PubMed ID: 20932009
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Novel 5-HT7 receptor inverse agonists. Synthesis and molecular modeling of arylpiperazine- and 1,2,3,4-tetrahydroisoquinoline-based arylsulfonamides.
    Vermeulen ES, van Smeden M, Schmidt AW, Sprouse JS, Wikström HV, Grol CJ.
    J Med Chem; 2004 Oct 21; 47(22):5451-66. PubMed ID: 15481983
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Role of 5-HT1B/D receptors in canine gastric accommodation: effect of sumatriptan and 5-HT1B/D receptor antagonists.
    De Ponti F, Crema F, Moro E, Nardelli G, Frigo G, Crema A.
    Am J Physiol Gastrointest Liver Physiol; 2003 Jul 21; 285(1):G96-104. PubMed ID: 12646419
    [Abstract] [Full Text] [Related]

  • 31. Structure-activity relationship studies of CNS agents, Part 31: Analogs of MP 3022 with a different number of nitrogen atoms in the heteroaromatic fragment--new 5-HT1A receptor ligands.
    Paluchowska MH, Dereń-Wesołek A, Mokrosz JL, Charakchieva-Minol S, Chojnacka-Wójcik E.
    Arch Pharm (Weinheim); 1996 Oct 21; 329(10):451-6. PubMed ID: 8933747
    [Abstract] [Full Text] [Related]

  • 32. N-Methyl-5-tert-butyltryptamine: A novel, highly potent 5-HT1D receptor agonist.
    Xu YC, Schaus JM, Walker C, Krushinski J, Adham N, Zgombick JM, Liang SX, Kohlman DT, Audia JE.
    J Med Chem; 1999 Feb 11; 42(3):526-31. PubMed ID: 9986723
    [Abstract] [Full Text] [Related]

  • 33. Synthesis and 5-HT3 receptor affinity of new quinolinecarboxylic acid derivatives.
    Orjales A, Alonso-Cires L, López-Tudanca PL, Tapia I, Labeaga L, Mosquera R.
    Drug Des Discov; 2000 Feb 11; 16(4):271-9. PubMed ID: 10807033
    [Abstract] [Full Text] [Related]

  • 34. New benzo[h][1,6]naphthyridine and azepino[3,2-c]quinoline derivatives as selective antagonists of 5-HT4 receptors: binding profile and pharmacological characterization.
    Hinschberger A, Butt S, Lelong V, Boulouard M, Dumuis A, Dauphin F, Bureau R, Pfeiffer B, Renard P, Rault S.
    J Med Chem; 2003 Jan 02; 46(1):138-47. PubMed ID: 12502367
    [Abstract] [Full Text] [Related]

  • 35. 2-(1-Naphthyloxy)ethylamines with enhanced affinity for human 5-HT1D beta (h5-HT1B) serotonin receptors.
    Ismaiel AM, Dukat M, Law H, Kamboj R, Fan E, Lee DK, Mazzocco L, Buekschkens D, Teitler M, Pierson ME, Glennon RA.
    J Med Chem; 1997 Dec 19; 40(26):4415-9. PubMed ID: 9435911
    [Abstract] [Full Text] [Related]

  • 36. In the search for selective ligands of 5-HT5, 5-HT6 and 5-HT7 serotonin receptors.
    Wesołowska A.
    Pol J Pharmacol; 2002 Dec 19; 54(4):327-41. PubMed ID: 12523486
    [Abstract] [Full Text] [Related]

  • 37. 3-(Arylsulfonyl)-1-(azacyclyl)-1H-indoles are 5-HT(6) receptor modulators.
    Bernotas RC, Antane S, Shenoy R, Le VD, Chen P, Harrison BL, Robichaud AJ, Zhang GM, Smith D, Schechter LE.
    Bioorg Med Chem Lett; 2010 Mar 01; 20(5):1657-60. PubMed ID: 20138763
    [Abstract] [Full Text] [Related]

  • 38. Novel and highly potent 5-HT3 receptor agonists based on a pyrroloquinoxaline structure.
    Campiani G, Cappelli A, Nacci V, Anzini M, Vomero S, Hamon M, Cagnotto A, Fracasso C, Uboldi C, Caccia S, Consolo S, Mennini T.
    J Med Chem; 1997 Oct 24; 40(22):3670-8. PubMed ID: 9357534
    [Abstract] [Full Text] [Related]

  • 39. 5-Thienyltryptamine derivatives as serotonin 5-HT1B/1D receptor agonists: potential treatments for migraine.
    Meng CQ, Rakhit S, Lee DK, Kamboj R, McCallum KL, Mazzocco L, Dyne K, Slassi A.
    Bioorg Med Chem Lett; 2000 May 01; 10(9):903-5. PubMed ID: 10853656
    [Abstract] [Full Text] [Related]

  • 40. Conformationally constrained N1-arylsulfonyltryptamine derivatives as 5-HT6 receptor antagonists.
    Cole DC, Lennox WJ, Stock JR, Ellingboe JW, Mazandarani H, Smith DL, Zhang G, Tawa GJ, Schechter LE.
    Bioorg Med Chem Lett; 2005 Nov 01; 15(21):4780-5. PubMed ID: 16125933
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.